New Immune Design Data Highlights Expanded Product Potential of ZVex® Platform at the 2016 SITC Annual Meeting
November 11 2016 - 8:00AM
Immune Design, a clinical-stage immunotherapy company focused on
oncology, today announced new preclinical data demonstrating the
ability of its ZVex discovery platform to induce immune responses
to multiple antigens co-delivered selectively to dendritic cells in
vivo. In addition, the company will present data on an alternate
prime boost approach than that currently under investigation in
Phase 2 studies. These data are being presented at the 31st
Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Conference taking place Nov. 9-13, 2016 in National Harbor,
Maryland.
“This advancement of the ZVex platform enables
the expression of potentially any combination of full-length
conserved tumor antigens, neo-epitopes and immune enhancers from a
single preparation, without resulting in antigen competition,” said
Jan ter Meulen, MD, PhD, Chief Scientific Officer at Immune Design.
“This allows us to target a wide range of tumors with either
off-the-shelf products or fully personalized therapies, thereby
representing a potentially significant step forward in the
evolution of our next-generation product development scope.”
Presentations
Immune Design scientists present data showing
that immunization with multi-genome ZVex vectors expressing
NY-ESO-1, MAGE-A3 and MAGE-A10 results in consistent induction of
polyfunctional CD8 T cells against all three antigens and
demonstrates significant improvement of immunogenicity by
co-expression of the cytokine IL-12. Immune responses were as high
as, or higher, than those obtained by combining individually
manufactured vectors, demonstrating the versatility and potency of
this multi-antigen ZVex approach.
In a second presentation highlighting an
alternate ZVex-based prime boost, Immune Design scientists present
data demonstrating in murine B16 and metastatic C26 colon carcinoma
models that priming with a ZVex vector carrying the RNA for a
tumor-associated antigen (TAA) and boosting with an adenoviral
vector (Ad5) encoding the same antigen resulted in increased
frequency of TAA-specific T cells and improved anti-tumor efficacy
over a prime-boost regimen with ZVex alone.
The poster presentations are titled:
“Multi-genome reassortant dendritic cell-tropic vector platform
(ZVex®) allows flexible co-expression of multiple antigens and
immune modulators for optimal induction of anti-tumor CD8+ T cell
responses” and “Heterologous boosts with an adenoviral vector
following a dendritic cell-tropic ZVex® prime generates robust
antigen-specific T cell responses and enhanced anti-tumor
protection.”
These posters will be posted on the publications page of the
Immune Design website following presentation at the conference.
About ZVex
ZVex is Immune Design’s discovery platform designed to activate
and expand the immune system’s natural ability to create
tumor-specific cytotoxic T cells (CTLs) in vivo. The
ZVex delivery system is designed to use a re-engineered virus to
carry genetic information of one or more conserved tumor antigens,
including neo-epitopes, as well as immune-modulatory molecules,
selectively to dendritic cells to create CTLs to target tumor cells
bearing that same tumor antigen(s).
About Immune Design
Immune Design is a clinical-stage immunotherapy company
employing next-generation in vivo approaches to enable the body's
immune system to fight disease. The company's technologies are
engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic T cells, while
also enhancing other immune effectors, to fight cancer and other
chronic diseases. CMB305 and G100, the primary focus of
Immune Design's ongoing immuno-oncology clinical programs, are
products of its two synergistic discovery platforms, ZVex® and
GLAASTM. Immune Design has offices in Seattle and South San
Francisco. For more information, visit www.immunedesign.com.
Forward Looking Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Immune
Design's expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
these forward-looking statements. Forward-looking statements
contained in this press release include, but are not limited to,
statements about the timing, progress, scope and outcome of
preclinical studies and the clinical application of Immune
Design's product candidates and technology platforms. Many
factors may cause differences between current expectations and
actual results including unexpected safety or efficacy data
observed during preclinical or clinical studies, changes in
expected or existing competition, changes in the regulatory
environment and unexpected litigation or other disputes. Success in
preclinical testing and early clinical trials does not ensure that
later clinical trials will be successful. Other factors that may
cause Immune Design's actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Immune Design's filings
with the U.S. Securities and Exchange Commission, including
the "Risk Factors" sections contained therein. Except as required
by law, Immune Design assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Contact for Immune Design:
Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206.769.9219
Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Apr 2023 to Apr 2024